Full Press Release Details
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics.
ZYME
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
Key Takeaway: Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers